<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Rijswijk, A.L. van</title>
    <link>http://repub.eur.nl/res/aut/16026/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Differential expression of protease activity in serum samples of prostate carcinoma patients with metastases (Article)</title>
      <link>http://repub.eur.nl/res/pub/20319/</link>
      <pubDate>2010-06-01T00:00:00Z</pubDate>
      <description>We present here the results from MS peptide profiling experiments of prostate carcinoma patients and controls with a specific focus on protease activity-related protein fragments. After purification with surface-active magnetic beads, MALDI-TOF profiling experiments were performed on tryptic digests of serum samples of prostate cancer patients with metastases (n = 27) and controls (n = 30). This resulted in the reproducible detection of eight differentially expressed peptides, which were then identified by nanoLC-MALDI-TOF/TOF and confirmed by MALDI-FTMS exact mass measurements. All differentially expressed peptides are derived from two homologous parts of human serum albumin; two of the eight peptides were tryptic and six were nontryptic. The presence of the nontryptic fragments indicates that a proteolysis process occurs which is not mediated by trypsin. Since the nontryptic fragments were found at significantly higher levels in control samples compared with metastases samples, it is proposed that a specific proteolytic inhibition process is in effect in the serum of prostate cancer patients. Experiments using synthetic peptides showed that this proteolytic activity occurs ex vivo and is sequence specific. Importantly, the observed prostate carcinomarelated inhibition of the proteolysis was reproduced ex vivo using synthetic peptides.</description>
    </item> <item>
      <title>Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins (Article)</title>
      <link>http://repub.eur.nl/res/pub/25192/</link>
      <pubDate>2009-06-01T00:00:00Z</pubDate>
      <description>Novel markers for prostate cancer (PCa) are needed because current established markers such as prostate-specific antigen lack diagnostic specificity and prognostic value. Proteomics analysis of serum from mice grafted with human PCa xenografts resulted in the identification of 44 tumor-derived proteins. Besides secreted proteins we identified several cytoplasmic proteins, among which were most subunits of the proteasome. Native gel electrophoresis and sandwich ELISA showed that these subunits are present as proteasome complexes in the serum from xenograft-bearing mice. We hypothesized that the presence of proteasome subunits and other cytoplasmic proteins in serum of xenografted mice could be explained by the secretion of small vesicles by cancer cells, so-called exosomes. Therefore, mass spectrometry and Western blotting analyses of the protein content of exosomes isolated from PCa cell lines was performed. This resulted in the identification of mainly cytoplasmic proteins of which several had previously been identified in the serum of xenografted mice, including proteasome subunits. The isolated exosomes also contained RNA, including the gene fusion TMPRSS2-ERG product. These observations suggest that although their function is not clearly defined cancer-derived exosomes offer possibilities for the identification of novel biomarkers for PCa. </description>
    </item> <item>
      <title>A small chimeric promoter for high prostate-specific transgene expression from adenoviral vectors (Article)</title>
      <link>http://repub.eur.nl/res/pub/35945/</link>
      <pubDate>2007-06-01T00:00:00Z</pubDate>
      <description>BACKGROUND. Specificity of transgene expression is important for safety during gene therapeutical applications. For prostate cancer, transcriptional targeting has been applied but was hampered by loss of specificity and low activity. We constructed a small chimeric promoter for high and prostate-specific transgene expression from adenoviral vectors. METHODS. A chimeric promoter, composed of the prostate-specific antigen (PSA) enhancer and the rat probasin promoter, was cloned into an adenoviral vector and its activity was compared to vectors containing conventional prostate-specific promoters and the constitutive Cytomegalovirus (CMV) promoter in in vitro and in vivo prostate cancer models. RESULTS. The chimeric PSA-probasin promoter was the most active prostate-specific promoter reaching up to 20% of CMV promoter activity while maintaining prostate-specificity. CONCLUSIONS. The chimeric PSA-probasin promoter is a small promoter that can be utilized in viral vectors for high prostate-specific transgene expression. </description>
    </item> <item>
      <title>Depletion of high-abundance proteins from serum by immunoaffinity chromatography: A MALDI-FT-MS study (Article)</title>
      <link>http://repub.eur.nl/res/pub/37057/</link>
      <pubDate>2007-02-15T00:00:00Z</pubDate>
      <description>Immunodepletion of high-abundance proteins from serum is a widely used initial step in biomarker discovery studies. In the present work we have investigated the reproducibility of the depletion step by comparing 250 serum samples from prostate cancer patients. All samples were depleted on a single immunoaffinity column over a time period of 6 weeks with automated peak detection and fraction collection. Reproducibility in terms of surface area of the depleted serum protein peak at 280 nm was below 7% relative standard deviation (R.S.D.) and the collected volume of the relevant fraction was 0.97 mL (4.5% R.S.D.). Proteins in the depleted serum fraction were subsequently digested with trypsin and analyzed by MALDI-FT-MS. The degree of the depletion of albumin, transferrin and alpha-1-antitrypsin was determined by comparing the intensity of peptide peaks before and after depletion of 11 samples taken at regular time intervals from amongst the 250 depleted, randomized samples. As a positive control we evaluated peaks of apolipoprotein A1 (the most abundant serum protein remaining after depleteion) showing a clear increase in intensity of these peaks in the depleted samples. From this study we conclude that the depletion of the 250 serum samples was complete and reproducible over a period of 6 weeks. </description>
    </item> <item>
      <title>Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice. (Article)</title>
      <link>http://repub.eur.nl/res/pub/14009/</link>
      <pubDate>2006-10-01T00:00:00Z</pubDate>
      <description>Lack of sensitivity and specificity of current tumor markers has intensified research efforts to find new biomarkers. The identification of potential tumor markers in human body fluids is hampered by large variability and complexity of both control and patient samples, laborious biochemical analyses, and the fact that the identified proteins are unlikely produced by the diseased cells but are due to secondary body defense mechanisms. In a new approach presented here, we eliminate these problems by performing proteomic analysis in a prostate cancer xenograft model in which human prostate cancer cells form a tumor in an immune-incompetent nude mouse. Using this concept, proteins present in mouse serum that can be identified as human will, by definition, originate from the human prostate cancer xenograft and might have potential diagnostic and prognostic value. Using one-dimensional gel electrophoresis, liquid chromatography, and mass spectrometry, we identified tumor-derived human nm23/nucleoside-diphosphate kinase (NME) in the serum of a nude mouse bearing the androgen-independent human prostate cancer xenograft PC339. NME is known to be involved in the metastatic potential of several tumor cells, including prostate cancer cells. Furthermore we identified six human enzymes involved in glycolysis (fructose-bisphosphate aldolase A, triose-phosphate isomerase, glyceraldehyde-3-phosphate dehydrogenase, alpha enolase, and lactate dehydrogenases A and B) in the serum of the tumor-bearing mice. The presence of human NME and glyceraldehyde-3-phosphate dehydrogenase in the serum of PC339-bearing mice was confirmed by Western blotting. Although the putative usefulness of these proteins in predicting prognosis of prostate cancer remains to be determined, the present data illustrate that our approach is a promising tool for the focused discovery of new prostate cancer biomarkers.</description>
    </item> <item>
      <title>A database application for pre-processing, storage and comparison of mass spectra derived from patients and controls. (Article)</title>
      <link>http://repub.eur.nl/res/pub/14086/</link>
      <pubDate>2006-09-05T00:00:00Z</pubDate>
      <description>BACKGROUND: Statistical comparison of peptide profiles in biomarker discovery requires fast, user-friendly software for high throughput data analysis. Important features are flexibility in changing input variables and statistical analysis of peptides that are differentially expressed between patient and control groups. In addition, integration the mass spectrometry data with the results of other experiments, such as microarray analysis, and information from other databases requires a central storage of the profile matrix, where protein id's can be added to peptide masses of interest. RESULTS: A new database application is presented, to detect and identify significantly differentially expressed peptides in peptide profiles obtained from body fluids of patient and control groups. The presented modular software is capable of central storage of mass spectra and results in fast analysis. The software architecture consists of 4 pillars, 1) a Graphical User Interface written in Java, 2) a MySQL database, which contains all metadata, such as experiment numbers and sample codes, 3) a FTP (File Transport Protocol) server to store all raw mass spectrometry files and processed data, and 4) the software package R, which is used for modular statistical calculations, such as the Wilcoxon-Mann-Whitney rank sum test. Statistic analysis by the Wilcoxon-Mann-Whitney test in R demonstrates that peptide-profiles of two patient groups 1) breast cancer patients with leptomeningeal metastases and 2) prostate cancer patients in end stage disease can be distinguished from those of control groups. CONCLUSION: The database application is capable to distinguish patient Matrix Assisted Laser Desorption Ionization (MALDI-TOF) peptide profiles from control groups using large size datasets. The modular architecture of the application makes it possible to adapt the application to handle also large sized data from MS/MS- and Fourier Transform Ion Cyclotron Resonance (FT-ICR) mass spectrometry experiments. It is expected that the higher resolution and mass accuracy of the FT-ICR mass spectrometry prevents the clustering of peaks of different peptides and allows the identification of differentially expressed proteins from the peptide profiles.</description>
    </item> <item>
      <title>The murine homologue of HIRA, a DiGeorge syndrome candidate gene, is expressed in embryonic structures affected in human CATCH22 patients (Article)</title>
      <link>http://repub.eur.nl/res/pub/8655/</link>
      <pubDate>1997-01-01T00:00:00Z</pubDate>
      <description>A wide spectrum of birth defects is caused by deletions of the DiGeorge
          syndrome chromosomal region at 22q11. Characteristic features include
          cranio-facial, cardiac and thymic malformations, which are thought to
          arise form disturbances in the interactions between hindbrain neural crest
          cells and the endoderm of the pharyngeal pouches. Several genes have been
          identified in the shortest region of deletion overlap at 22q11, but
          nothing is known about the expression of these genes in mammalian embryos.
          We report here the isolation of several murine embryonic cDNAs of the
          DiGeorge syndrome candidate gene HIRA. We identified several alternatively
          spliced transcripts. Sequence analysis reveals that Hira bears homology to
          the p60 subunit of the human Chromatin Assembly Factor I and yeast hir1p
          and Hir2p, suggesting that Hira might have some role in chromatin assembly
          and/or histone regulation. Whole mount in situ hybridization of mouse
          embryos at various stages of development show that Hira is ubiquitously
          expressed. However, higher levels of transcripts are detected in the
          cranial neural folds, frontonasal mass, first two pharyngeal arches,
          circumpharyngeal neural crest and the limb buds. Since many of the
          structures affected in DiGeorge syndrome derive from these Hira expressing
          cell populations we propose that haploinsufficiency of HIRA contributes to
          at least some of the features of the DiGeorge phenotype.</description>
    </item>
  </channel>
</rss>